vs

Side-by-side financial comparison of IDEX Corporation (IEX) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $398.4M, roughly 3.6× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs 27.6%, a 2.5% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 11.0%). Over the past eight quarters, ResMed's revenue compounded faster (7.9% CAGR vs -29.4%).

IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

IEX vs RMD — Head-to-Head

Bigger by revenue
RMD
RMD
3.6× larger
RMD
$1.4B
$398.4M
IEX
Growing faster (revenue YoY)
IEX
IEX
+5.7% gap
IEX
16.7%
11.0%
RMD
Higher net margin
IEX
IEX
2.5% more per $
IEX
30.1%
27.6%
RMD
Faster 2-yr revenue CAGR
RMD
RMD
Annualised
RMD
7.9%
-29.4%
IEX

Income Statement — Q2 FY2026 vs Q4 FY2026

Metric
IEX
IEX
RMD
RMD
Revenue
$398.4M
$1.4B
Net Profit
$120.0M
$392.6M
Gross Margin
99.9%
61.8%
Operating Margin
43.3%
34.6%
Net Margin
30.1%
27.6%
Revenue YoY
16.7%
11.0%
Net Profit YoY
25.7%
13.9%
EPS (diluted)
$1.61
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IEX
IEX
RMD
RMD
Q2 26
$398.4M
$1.4B
Q1 26
$407.7M
Q4 25
$899.1M
$1.4B
Q3 25
$878.7M
$1.3B
Q2 25
$865.4M
$1.3B
Q1 25
$814.3M
$1.3B
Q4 24
$862.9M
$1.3B
Q3 24
$798.2M
$1.2B
Net Profit
IEX
IEX
RMD
RMD
Q2 26
$120.0M
$392.6M
Q1 26
$128.3M
Q4 25
$128.3M
$392.6M
Q3 25
$127.8M
$348.5M
Q2 25
$131.6M
$379.7M
Q1 25
$95.5M
$365.0M
Q4 24
$123.2M
$344.6M
Q3 24
$119.1M
$311.4M
Gross Margin
IEX
IEX
RMD
RMD
Q2 26
99.9%
61.8%
Q1 26
94.9%
Q4 25
43.1%
61.8%
Q3 25
44.5%
61.5%
Q2 25
45.3%
60.8%
Q1 25
45.3%
59.3%
Q4 24
42.5%
58.6%
Q3 24
44.3%
58.6%
Operating Margin
IEX
IEX
RMD
RMD
Q2 26
43.3%
34.6%
Q1 26
45.0%
Q4 25
20.4%
34.6%
Q3 25
21.1%
33.4%
Q2 25
21.7%
33.7%
Q1 25
17.4%
33.0%
Q4 24
19.2%
32.5%
Q3 24
21.0%
31.6%
Net Margin
IEX
IEX
RMD
RMD
Q2 26
30.1%
27.6%
Q1 26
31.5%
Q4 25
14.3%
27.6%
Q3 25
14.5%
26.1%
Q2 25
15.2%
28.2%
Q1 25
11.7%
28.3%
Q4 24
14.3%
26.9%
Q3 24
14.9%
25.4%
EPS (diluted)
IEX
IEX
RMD
RMD
Q2 26
$1.61
$2.68
Q1 26
$1.71
Q4 25
$1.71
$2.68
Q3 25
$1.70
$2.37
Q2 25
$1.74
$2.58
Q1 25
$1.26
$2.48
Q4 24
$1.61
$2.34
Q3 24
$1.57
$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IEX
IEX
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$586.2M
$1.4B
Total DebtLower is stronger
$663.8M
Stockholders' EquityBook value
$4.0B
$6.3B
Total Assets
$6.9B
$8.5B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IEX
IEX
RMD
RMD
Q2 26
$586.2M
$1.4B
Q1 26
$580.0M
Q4 25
$580.0M
$1.4B
Q3 25
$593.8M
$1.4B
Q2 25
$568.2M
$1.2B
Q1 25
$594.1M
$932.7M
Q4 24
$620.8M
$521.9M
Q3 24
$633.2M
$426.4M
Total Debt
IEX
IEX
RMD
RMD
Q2 26
$663.8M
Q1 26
Q4 25
$1.8B
$403.9M
Q3 25
$1.9B
$408.7M
Q2 25
$1.9B
$658.4M
Q1 25
$2.0B
$663.1M
Q4 24
$2.0B
$662.9M
Q3 24
$2.1B
$667.6M
Stockholders' Equity
IEX
IEX
RMD
RMD
Q2 26
$4.0B
$6.3B
Q1 26
$4.0B
Q4 25
$4.0B
$6.3B
Q3 25
$4.0B
$6.1B
Q2 25
$4.0B
$6.0B
Q1 25
$3.9B
$5.5B
Q4 24
$3.8B
$5.3B
Q3 24
$3.8B
$5.2B
Total Assets
IEX
IEX
RMD
RMD
Q2 26
$6.9B
$8.5B
Q1 26
$6.9B
Q4 25
$6.9B
$8.5B
Q3 25
$7.0B
$8.3B
Q2 25
$6.9B
$8.2B
Q1 25
$6.8B
$7.6B
Q4 24
$6.7B
$7.1B
Q3 24
$7.0B
$7.2B
Debt / Equity
IEX
IEX
RMD
RMD
Q2 26
0.11×
Q1 26
Q4 25
0.45×
0.06×
Q3 25
0.48×
0.07×
Q2 25
0.46×
0.11×
Q1 25
0.50×
0.12×
Q4 24
0.52×
0.13×
Q3 24
0.55×
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IEX
IEX
RMD
RMD
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$86.0M
FCF MarginFCF / Revenue
21.6%
Capex IntensityCapex / Revenue
4.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$654.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IEX
IEX
RMD
RMD
Q2 26
Q1 26
Q4 25
$209.5M
$339.7M
Q3 25
$203.5M
$457.3M
Q2 25
$161.7M
$538.8M
Q1 25
$105.7M
$578.7M
Q4 24
$172.6M
$308.6M
Q3 24
$205.3M
$325.5M
Free Cash Flow
IEX
IEX
RMD
RMD
Q2 26
$86.0M
Q1 26
$189.8M
Q4 25
$189.8M
$311.2M
Q3 25
$188.7M
$414.4M
Q2 25
$146.9M
$508.2M
Q1 25
$91.4M
$557.9M
Q4 24
$157.1M
$288.0M
Q3 24
$191.6M
$307.7M
FCF Margin
IEX
IEX
RMD
RMD
Q2 26
21.6%
Q1 26
46.6%
Q4 25
21.1%
21.9%
Q3 25
21.5%
31.0%
Q2 25
17.0%
37.7%
Q1 25
11.2%
43.2%
Q4 24
18.2%
22.5%
Q3 24
24.0%
25.1%
Capex Intensity
IEX
IEX
RMD
RMD
Q2 26
4.4%
Q1 26
15.6%
Q4 25
2.2%
2.0%
Q3 25
1.7%
3.2%
Q2 25
1.7%
2.3%
Q1 25
1.8%
1.6%
Q4 24
1.8%
1.6%
Q3 24
1.7%
1.5%
Cash Conversion
IEX
IEX
RMD
RMD
Q2 26
Q1 26
Q4 25
1.63×
0.87×
Q3 25
1.59×
1.31×
Q2 25
1.23×
1.42×
Q1 25
1.11×
1.59×
Q4 24
1.40×
0.90×
Q3 24
1.72×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons